Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Mark E. Hatley"'
Autor:
Madeline B. Searcy, Randolph K. Larsen, Bradley T. Stevens, Yang Zhang, Hongjian Jin, Catherine J. Drummond, Casey G. Langdon, Katherine E. Gadek, Kyna Vuong, Kristin B. Reed, Matthew R. Garcia, Beisi Xu, Darden W. Kimbrough, Grace E. Adkins, Nadhir Djekidel, Shaina N. Porter, Patrick A. Schreiner, Shondra M. Pruett-Miller, Brian J. Abraham, Jerold E. Rehg, Mark E. Hatley
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-23 (2023)
Abstract Fusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive subtype of pediatric rhabdomyosarcoma. FP-RMS histologically resembles developing muscle yet occurs throughout the
Externí odkaz:
https://doaj.org/article/af11c11b372b412d83edd57dfaac71cf
Autor:
Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, William C. Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy, Tanja A. Gruber
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
KMT2A rearranged infant acute lymphoblastic leukemia patients have a poor prognosis. Here, the authors use high throughput drug screening on primary infant specimens to identify a clinically active chemotherapy combination.
Externí odkaz:
https://doaj.org/article/2cd886b587c94bdaa2bd04fdff849913
Autor:
Casey G. Langdon, Katherine E. Gadek, Matthew R. Garcia, Myron K. Evans, Kristin B. Reed, Madeline Bush, Jason A. Hanna, Catherine J. Drummond, Matthew C. Maguire, Patrick J. Leavey, David Finkelstein, Hongjian Jin, Patrick A. Schreiner, Jerold E. Rehg, Mark E. Hatley
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
PTEN copy number loss is found in 25% of fusion-negative rhabdomyosarcomas (FN-RMS). Here, the authors use a Hedgehog-driven FN-RMS mouse model to show that PTEN loss drives the expression of core transcription factor PAX7 and its transcriptional axi
Externí odkaz:
https://doaj.org/article/0413e8410b0248ed86492edc2f4f4634
Autor:
Jennifer L. Kamens, Stephanie Nance, Cary Koss, Beisi Xu, Anitria Cotton, Jeannie W. Lam, Elizabeth A. R. Garfinkle, Pratima Nallagatla, Amelia M. R. Smith, Sharnise Mitchell, Jing Ma, Duane Currier, William C. Wright, Kanisha Kavdia, Vishwajeeth R. Pagala, Wonil Kim, LaShanale M. Wallace, Ji-Hoon Cho, Yiping Fan, Aman Seth, Nathaniel Twarog, John K. Choi, Esther A. Obeng, Mark E. Hatley, Monika L. Metzger, Hiroto Inaba, Sima Jeha, Jeffrey E. Rubnitz, Junmin Peng, Taosheng Chen, Anang A. Shelat, R. Kiplin Guy, Tanja A. Gruber
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/9c447ea95d6141ec876fcaed7f440b4c
Autor:
Casey G. Langdon, Mark E. Hatley
Publikováno v:
Molecular & Cellular Oncology, Vol 8, Iss 6 (2021)
Fusion-negative rhabdomyosarcoma (FN-RMS) is molecularly heterogeneous with few universal alterations except for Phosphatase and tensin homolog (PTEN) promoter hypermethylation. We demonstrate that losing Pten in FN-RMS engages an aberrant transcript
Externí odkaz:
https://doaj.org/article/92e225a014bf42b9929b5df3138fe889
Autor:
Catherine J. Drummond, Mark E. Hatley
Publikováno v:
Molecular & Cellular Oncology, Vol 5, Iss 4 (2018)
Rhabdomyosarcoma (RMS) histologically resembles developing skeletal muscle and is thought to solely originate from a differentiation block in muscle progenitors. We demonstrate that RMS can arise from endothelial progenitor cells following reprogramm
Externí odkaz:
https://doaj.org/article/aa43b7ae2e3d481d95f1a2657fa850e6
Autor:
Mark E. Hatley, Jerold E. Rehg, David Finkelstein, Jonathan C. Go, Matthew R. Garcia, Catherine J. Drummond, Jason A. Hanna
Angiosarcoma is an aggressive vascular sarcoma with an extremely poor prognosis. Because of the relative rarity of this disease, its molecular drivers and optimal treatment strategies are obscure. DICER1 is an RNase III endoribonuclease central to mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60f726706e802599f3ac8d6c8ea7f10f
https://doi.org/10.1158/0008-5472.c.6509529
https://doi.org/10.1158/0008-5472.c.6509529
Autor:
Mark E. Hatley, Jerold E. Rehg, David Finkelstein, Jonathan C. Go, Matthew R. Garcia, Catherine J. Drummond, Jason A. Hanna
This file contains four supplementary tables and four supplementary figures pertinent to the submitted manuscript as follows: Table S1 lists the Enrichr analysis of miRNA targets in angiosarcoma. Table S2 lists the antibodies used for immunohistochem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3ffa0c6d904f8111713e34b5b71bb2
https://doi.org/10.1158/0008-5472.22416348
https://doi.org/10.1158/0008-5472.22416348
Autor:
Jason A Hanna, Casey G Langdon, Matthew R Garcia, Annaleigh Benton, Nadia A Lanman, David Finkelstein, Jerold E Rehg, Mark E Hatley
Publikováno v:
The Journal of Pathology. 257:109-124
Angiosarcomas are aggressive vascular sarcomas that arise from endothelial cells and have an extremely poor prognosis. Because of the rarity of angiosarcomas, knowledge of molecular drivers and optimized treatment strategies is lacking, highlighting
Autor:
Casey G. Langdon, Mark E. Hatley
Publikováno v:
Molecularcellular oncology. 8(6)
Fusion-negative rhabdomyosarcoma (FN-RMS) is molecularly heterogeneous with few universal alterations except for Phosphatase and tensin homolog (PTEN) promoter hypermethylation. We demonstrate that...